ECSP088972A - ISOINDOLS REPLACED AS BACE INHIBITORS AND THEIR USE - Google Patents

ISOINDOLS REPLACED AS BACE INHIBITORS AND THEIR USE

Info

Publication number
ECSP088972A
ECSP088972A EC2008008972A ECSP088972A ECSP088972A EC SP088972 A ECSP088972 A EC SP088972A EC 2008008972 A EC2008008972 A EC 2008008972A EC SP088972 A ECSP088972 A EC SP088972A EC SP088972 A ECSP088972 A EC SP088972A
Authority
EC
Ecuador
Prior art keywords
isoindols
replaced
bace inhibitors
new compounds
bace
Prior art date
Application number
EC2008008972A
Other languages
Spanish (es)
Inventor
James Arnold
Laszlo Rakos
Didier Rotticci
Stefan Berg
Christopher William Murray
Gianni Chessari
Miles Stuart Congreve
Karin Kolmodin
Sahil Patel
Joerg Holens
Phil Edwards
Annika Kers
Mark Sylvester
Liselotte Oehberg
Original Assignee
Astrazeneca Ab
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astex Therapeutics Ltd filed Critical Astrazeneca Ab
Publication of ECSP088972A publication Critical patent/ECSP088972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a nuevos compuestos que tienen la estructura de fórmula I y sus sales farmacéuticamente aceptables, composiciones y métodos de uso. Estos nuevos compuestos proporcionan un tratamiento o profilaxis de deterioros cognitivos, enfermedad de Alzheimer, neurodegeneración y demencia.This invention relates to new compounds having the structure of formula I and their pharmaceutically acceptable salts, compositions and methods of use. These new compounds provide a treatment or prophylaxis of cognitive impairments, Alzheimer's disease, neurodegeneration and dementia.

EC2008008972A 2006-06-22 2008-12-12 ISOINDOLS REPLACED AS BACE INHIBITORS AND THEIR USE ECSP088972A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81580006P 2006-06-22 2006-06-22
US81855706P 2006-07-05 2006-07-05
US89124207P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
ECSP088972A true ECSP088972A (en) 2009-01-30

Family

ID=38833680

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008972A ECSP088972A (en) 2006-06-22 2008-12-12 ISOINDOLS REPLACED AS BACE INHIBITORS AND THEIR USE

Country Status (17)

Country Link
US (2) US7855213B2 (en)
EP (1) EP2035378A4 (en)
JP (1) JP2009541311A (en)
KR (1) KR20090031585A (en)
AR (1) AR061564A1 (en)
AU (1) AU2007261749B2 (en)
CA (1) CA2656625A1 (en)
CL (1) CL2007001830A1 (en)
EC (1) ECSP088972A (en)
IL (1) IL195670A0 (en)
MX (1) MX2008015719A (en)
MY (1) MY147390A (en)
NO (1) NO20090246L (en)
NZ (1) NZ574262A (en)
TW (1) TW200815349A (en)
UY (1) UY30426A1 (en)
WO (1) WO2007149033A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
WO2006138265A2 (en) * 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
PE20070135A1 (en) 2005-06-14 2007-03-09 Schering Corp HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES
PE20080155A1 (en) 2006-06-12 2008-03-10 Schering Corp HETEROCYCLIC COMPOUNDS AS ASPARTILE-PROTEASE INHIBITORS
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005471A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005470A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
CA2723222C (en) 2008-04-22 2013-04-02 Schering Corporation Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
MY148558A (en) 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
MX2011004680A (en) * 2008-11-06 2011-05-25 Astrazeneca Ab Modulators of amyloid beta.
WO2010056195A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
WO2011002409A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
UA108363C2 (en) 2009-10-08 2015-04-27 IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US20110281894A1 (en) * 2010-05-12 2011-11-17 Astrazeneca Ab Hemifumarate salt
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103874496A (en) 2011-08-22 2014-06-18 默沙东公司 2-spiro-substituted iminothiazines as BACE inhibitors and their mono- and dioxide-oxides, compositions and uses thereof
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN104270945B (en) 2012-03-19 2017-03-29 巴克老龄化研究所 APP-specific BACE inhibitors (ASBI) and uses thereof
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9422277B2 (en) 2012-10-17 2016-08-23 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN121240860A (en) * 2023-05-16 2025-12-30 斯普林渥克斯治疗有限公司 Benzimidazole and related analogues used to inhibit YAP/TAZ-TEAD

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE4419849A1 (en) 1994-06-07 1995-12-14 Hoechst Ag Isoindoline pigments
DK0765327T3 (en) 1994-06-16 1999-11-29 Pfizer Pyrazolo and pyrrolopyridines
DE19516804A1 (en) 1995-05-08 1996-11-14 Hoechst Ag Isoindoline pigments based on aminoquinoxalinediones
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (en) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β-secretase, antibodies to β-secretase, and assays for detecting β-secretase inhibition
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
PL205294B1 (en) 1998-09-24 2010-03-31 Upjohn Co Alzheimer's disease secretase
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
JP2003502342A (en) 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド Statin-induced tetrapeptide inhibitors of beta-secretase
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
WO2001023533A2 (en) 1999-09-23 2001-04-05 Pharmacia & Upjohn Company Alzheimer's disease secretase, app substrates therefor, and uses therefor
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
JP2004502664A (en) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド Compound for treating Alzheimer's disease
AU2001281250A1 (en) 2000-08-11 2002-02-25 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
WO2002025276A1 (en) 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
JP2004149429A (en) * 2002-10-29 2004-05-27 Takeda Chem Ind Ltd Indole compound and application thereof
EP2335701B1 (en) 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007530696A (en) 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド 2-Aminothiazole compounds useful as aspartic protease inhibitors
CA2562783A1 (en) * 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
JP2008502687A (en) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
BRPI0512213A (en) 2004-06-16 2008-02-19 Wyeth Corp method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
RU2006144075A (en) 2004-06-16 2008-07-27 Вайет (Us) DIPHENYLIMIDAZOPYRIMIDINE AND β-IMIDAZOLAMINES AS β-SECRETASE INHIBITORS
JPWO2006006520A1 (en) 2004-07-09 2008-04-24 株式会社ジェノファンクション New drug discovery method
DE112005001528T5 (en) 2004-07-12 2007-05-24 Dai Nippon Printing Co., Ltd. Shielding filter for electromagnetic waves
DE602005023887D1 (en) * 2004-08-06 2010-11-11 Janssen Pharmaceutica Nv ALSO B-SECRETASE (BACE) NON-USEFUL 2-AMINO-CHINAZOLE DERIVATIVES
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
JP2008516945A (en) 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ Substituted amino compounds and their use
EP1802588A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
US20080287399A1 (en) 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof
CA2593515A1 (en) 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
KR20080025079A (en) 2005-06-14 2008-03-19 쉐링 코포레이션 Aspartyl Protease Inhibitor
PE20070135A1 (en) 2005-06-14 2007-03-09 Schering Corp HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES
AR053902A1 (en) 2005-06-14 2007-05-23 Schering Corp INHIBITORS OF ASPARTILLE PROTEASA MACROCICLIC HETEROCICLICS
ATE489370T1 (en) 2005-06-14 2010-12-15 Schering Corp PREPARATION AND USE OF COMPOUNDS AS ASPARTYL PROTEASE INHIBITORS
EP1896406A2 (en) 2005-06-14 2008-03-12 Shering Corporation The preparation and use of compounds as protease inhibitors
WO2006138265A2 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
JP2009502786A (en) 2005-07-18 2009-01-29 メルク エンド カムパニー インコーポレーテッド Spiropiperidine β-secretase inhibitors for treating Alzheimer's disease
US7601751B2 (en) 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
CA2628074C (en) * 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
ATE478070T1 (en) 2005-10-27 2010-09-15 Schering Corp HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS
JP2009513670A (en) 2005-10-31 2009-04-02 シェーリング コーポレイション Aspartyl protease inhibitor
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
JP2009515950A (en) 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ Novel 2-aminopyrimidine derivatives and uses thereof
EP1951680A4 (en) 2005-11-15 2011-08-10 Astrazeneca Ab Novel 2-aminopyrimidinone derivatives and their use
CN101360721A (en) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 Novel 2-aminopyrimidinone derivatives or 2-aminopyridone derivatives and uses thereof
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
AR058381A1 (en) 2005-12-19 2008-01-30 Astrazeneca Ab COMPOUNDS DERIVED FROM 2-AMINOPIRIDIN-4-ONAS AND A PHARMACEUTICAL COMPOSITION
CN101460480A (en) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-aminopyrimidin-4-ones and their use for treating or preventing a beta-related pathologies
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
PE20080155A1 (en) 2006-06-12 2008-03-10 Schering Corp HETEROCYCLIC COMPOUNDS AS ASPARTILE-PROTEASE INHIBITORS
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005471A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005470A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2010056195A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574

Also Published As

Publication number Publication date
CA2656625A1 (en) 2007-12-27
US7855213B2 (en) 2010-12-21
UY30426A1 (en) 2008-01-31
TW200815349A (en) 2008-04-01
AU2007261749A1 (en) 2007-12-27
US20080171771A1 (en) 2008-07-17
CL2007001830A1 (en) 2008-04-04
EP2035378A1 (en) 2009-03-18
MY147390A (en) 2012-11-30
AR061564A1 (en) 2008-09-03
IL195670A0 (en) 2009-09-01
AU2007261749B2 (en) 2011-11-03
NZ574262A (en) 2011-11-25
NO20090246L (en) 2009-03-20
US20110059992A1 (en) 2011-03-10
EP2035378A4 (en) 2012-01-25
MX2008015719A (en) 2009-01-09
KR20090031585A (en) 2009-03-26
WO2007149033A1 (en) 2007-12-27
JP2009541311A (en) 2009-11-26

Similar Documents

Publication Publication Date Title
ECSP088972A (en) ISOINDOLS REPLACED AS BACE INHIBITORS AND THEIR USE
ECSP099755A (en) DERIVATIVES OF PIRROLOPIRIDINE AND ITS USE AS BACE INHIBITORS
UY29927A1 (en) SUBSTITUTED DERIVATIVES OF 5-FENIL-2-TIOXO-IMIDAZOLIN-4-ONA AND 5-FENIL-2-AMINO-IMIDAZOLIDIN-4-ONA AND ITS SALTS, COMPOSITIONS AND APPLICATIONS
UY31083A1 (en) SULFOXIMINAL DERIVATIVES FOR THE INHIBITION OF B-SECRETASE
ECSP088969A (en) AMINO-IMIDAZOLONES AND ITS USE AS A MEDICINAL PRODUCT TO TREAT COGNITIVE DEFICIENCIES, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
ECSP088970A (en) AMINO-IMIDAZOLONAS AND ITS USE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF COGNITIVE DEFICIENCY, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
UY29919A1 (en) SUBSTITUTED DERIVATIVES OF 3,4-DIHYDROISOQUINOLIN-1-AMINO-TRIFLUOROACETATE, ITS PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS
MX388468B (en) MULTICYCLIC COMPOUNDS AND METHODS OF USING THEM.
UY30025A1 (en) SUBSTITUTED DERIVATIVES OF 2-AMINO-5,6-DIHIDRO PIRIMIDIN-4 (3H) -ONAS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING AND APPLICATIONS.
UY30274A1 (en) SUBSTITUTED DERIVATIVES OF THE N- (4-METHYL-1,3-TIAZOL-2-IL) GUANIDINE, PHARMACEUTICAL FORMULATIONS CONTAINING IT AND APPLICATIONS
UY30407A1 (en) DERIVATIVES OF [2,3,4,8-TETRAHYDROIMIDAZO- [1,5-A] -PIRIMIDIN-8-IL] -FENIL SUBSTITUTED SULPHONATES, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS.
UY32730A (en) CYP17 INHIBITORS
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
NO20081554L (en) Isoindollide compounds and compositions comprising the same, and their use
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
EA200900213A1 (en) REVERSE MOTORS
EA200800760A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2008013196A (en) 5-amido-2-carboxamide indoles.
MX2009003645A (en) N-substituted-azacyclylamines as histamine-3 antagonists.
CR11157A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
ATE466854T1 (en) 1H-INDOLE-6-YLPIPERAZINE-1-YLMETHANONE DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS
CL2008001990A1 (en) Compounds derived from substituted amino-quinazolines; pharmaceutical composition comprising said compound; and use of the compound for the treatment of Alzheimer's.
DE602007011434D1 (en) 1H-indol-5-yl-piperazin-1-YLMETHANONDERIVATE